Compare Diamondback Energy Inc (FANG) vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Diamondback Energy Inc vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) — how do they compare? Diamondback Energy Inc trades at $192.13 (market cap $53.67B), while Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) trades at $18.73 (market cap $58.74B). The key difference: Diamondback Energy Inc and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) are close in size by market cap, and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) pays the higher dividend (3.33%). Which is the better fit depends on your goals — on Pluang, investors hold Diamondback Energy Inc for 69 Days and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) for 1 Days on average.
| FANG | TAK | |
|---|---|---|
Market Cap | $53.67B | $58.74B |
Volume | 2,250,644 | 3,110,994 |
Sector | Energy | Health |
52-Week High | $213.69 | $19.05 |
52-Week Low | $137.29 | $13.23 |
Typical Hold Time | 69 Days | 1 Days |
Enterprise Value | $65.83B | $86.65B |
Dividend Yield | 2.3% | 3.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Diamondback Energy (FANG) trades at $191.68, up 3.96% today, with strong analyst support (90.57% buy rating) and a $231.77 consensus price target. The stock shows bullish technical momentum above key support at $189, while fundamentals reveal robust revenue growth from $14.93B in 2025 to projected $17.0B in 2026, though net margins have compressed. Recent Q2 2026 earnings beat expectations at $6.48 EPS, and the company maintains solid cash flow generation with $8.76B from operations in 2025.
FANG presents a compelling growth opportunity with Permian Basin dominance and positive earnings momentum, but investors face risks from oil price volatility and insider selling. The stock's current valuation at 36.51 P/E requires sustained execution to justify upside, while technical indicators suggest near-term resistance at $193-197 levels.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Diamondback Energy Inc
Diamondback Energy is an independent oil and gas producer in the United States. The company operates exclusively in the Permian Basin. At the end of 2021, the company reported net proven reserves of 1.8 billion barrels of oil equivalent. Net production averaged about 375,000 barrels per day in 2021, at a ratio of 60% oil, 20% natural gas liquids, and 20% natural gas.
Read more on FANG →About Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)
Takeda is a Japanese pharmaceutical company developing medicines across areas including gastrointestinal disease, rare diseases, neuroscience, oncology, and plasma-derived therapies.
Read more on TAK →
